US Thrombus Treatment Market

Several factors contribute to the substantial market share of the thrombus treatment sector, particularly in North America. These include a well-established healthcare infrastructure, the availability of research grants for developing safe and effective thrombus treatments, and the increasing numbers of elderly and obese individuals in the region. To illustrate, data from the World Health Organization (WHO) in 2021 indicates a significant rise in the population over 80 years in North America, expected to triple from 143 million in 2019 to 426 million in 2050. This demographic shift, characterized by an aging and obese population, acts as a driving force for the growth of the thrombus treatment market.

According to the National Health and Nutrition Examination Survey (NHANES) conducted in 2017–2018, the prevalence of obesity in the United States is a pressing concern. The survey revealed that one in every three adults was considered overweight, and approximately one in eleven adults was dealing with extreme obesity. Furthermore, a staggering 42.5% of US adults aged 20 and over were reported to be suffering from obesity, including 9.0% with severe obesity. Another 31.1% fell into the overweight category. This increase in obesity rates over the past decade not only signifies a significant shift in the market but also poses a heightened risk of developing high blood pressure in veins, leading to various thrombus-related complications. Thus, the growing burden of obesity serves as a driving factor for the thrombus treatment market.

Moreover, the region boasts the presence of key players such as Johnson & Johnson and Bristol-Myers Squibb, further contributing to the growth of the thrombus treatment market in North America. These industry leaders play a crucial role in advancing medical solutions and driving innovation within the market. Additionally, the trend of companies forming partnerships and making substantial investments in research and development is gaining momentum. As an example, Imperative Care Inc. received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2022 for the prodigy thrombectomy system. This system is designed to address peripheral vascular thrombus, showcasing the commitment of companies to introduce advanced treatment options and, in turn, propel the thrombus treatment market in the region.

North America's significant market share in the thrombus treatment sector can be attributed to various factors, including a robust healthcare infrastructure, research grants supporting treatment development, and the growing elderly and obese population. The demographic shift towards an aging population, as highlighted by WHO projections, coupled with rising obesity rates, underscores the pressing need for effective thrombus treatments. The presence of major players like Johnson & Johnson, coupled with ongoing research and development efforts and strategic partnerships, positions North America as a key region driving the growth of the thrombus treatment market. As innovations continue to emerge and gain regulatory approval, the market is poised to address the evolving healthcare needs of the population, ensuring advancements in thrombus treatment and improved patient outcomes.